Welcome to our dedicated page for Harmony Biosciences Holdings news (Ticker: HRMY), a resource for investors and traders seeking the latest updates and insights on Harmony Biosciences Holdings stock.
Harmony Biosciences Holdings, Inc. (HRMY) delivers innovative therapies for rare neurological and central nervous system disorders, with a focus on sleep/wake conditions. This page provides authorized updates on clinical developments, regulatory milestones, and corporate announcements directly impacting the company serves.
Investors and healthcare professionals will find timely updates on WAKIX commercialization, pipeline advancements in rare epilepsies, and strategic collaborations. Content includes earnings reports, FDA filings, research publications, and partnership announcements—all verified through primary sources.
Key coverage areas include pediatric narcolepsy treatment expansions, orexin receptor agonist trials, and neurobehavioral disorder research. Bookmark this page for consolidated access to Harmony Biosciences' progress in transforming care for underserved patient populations through novel therapeutic mechanisms.
Harmony Biosciences (NASDAQ: HRMY) presented updated data from its Open-Label Extension (OLE) study of ZYN002 for Fragile X Syndrome (FXS) treatment. The study demonstrated clinically meaningful improvements in irritability-related symptoms in patients.
Key findings include:
- Over 60% of participants achieved clinically meaningful improvement of ≥9 points on ABC-CFXS Irritability scores
- After three years, ~73% of patients experienced clinically meaningful improvements
- Treatment-related adverse events occurred in 12.9% of patients, with application site pain being most common (6.7%)
The study included 240 patients aged 3-17 years, with data collected from September 2018 to January 2024. The company expects topline data from its Phase 3 RECONNECT study in Q3 2025. Currently, there are no FDA-approved treatments for FXS, which affects approximately 80,000 individuals in the U.S.
Harmony Biosciences (Nasdaq: HRMY) has appointed Ron Philip to its Board of Directors. Philip, currently President and CEO of Orbital Therapeutics, brings 30 years of experience in company building, organizational growth, and therapeutic development. His notable previous role was CEO of Spark Therapeutics, where he led the commercial launch of a novel gene therapy for inherited blindness and expanded the company's therapeutic platform.
Philip's extensive background includes leadership positions at Pfizer and Wyeth, serving as regional president for Africa/Middle East and heading various strategic initiatives. He currently serves on the boards of City Therapeutics and Life Sciences Cares Pennsylvania. The appointment aligns with Harmony's focus on pipeline expansion through business development, as the company aims to leverage Philip's expertise in identifying new technologies that benefit patients while creating shareholder value.
Harmony Biosciences (Nasdaq: HRMY) has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management team will engage in a fireside chat scheduled for Wednesday, April 9, 2025, at 3:00 p.m. ET.
Interested parties can access the webcast of the discussion through the investor relations section of Harmony's website at https://ir.harmonybiosciences.com/.
Harmony Biosciences (Nasdaq: HRMY) has appointed Adam Zaeske as Executive Vice President and Chief Commercial Officer (CCO), effective March 31, 2025, replacing Jeffrey Dierks who is stepping down for personal reasons.
Zaeske brings 25 years of pharmaceutical industry leadership experience, most recently serving as Head of Central, South, and Eastern Europe at Takeda Pharmaceuticals, where he managed a $2 billion business across 25 countries. At Harmony, he will lead the commercial organization, drive market expansion, and oversee execution across all brands and geographies.
The appointment comes as Harmony builds on the commercial success of WAKIX® (pitolisant) in narcolepsy and prepares to advance its late-stage pipeline assets. The company maintains its 2025 revenue guidance and projects WAKIX to be a $1B plus opportunity in adult narcolepsy alone.
Harmony Biosciences (Nasdaq: HRMY) has announced its management team's upcoming participation in two major healthcare investor conferences in Miami, FL. The company will attend the Barclays Global Healthcare Conference on Tuesday, March 11, 2025, followed by the Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025.
At the Leerink conference, Harmony will participate in a fireside chat scheduled for 1:00 p.m. ET. Investors can access the webcast of this discussion through the investor relations section of Harmony's website at ir.harmonybiosciences.com.
Harmony Biosciences reported strong financial results for 2024, with WAKIX® (pitolisant) generating $201.3 million in net revenue for Q4 and $714.7 million for the full year, representing 23% growth in its fifth year on the market. The company reiterated its 2025 WAKIX net revenue guidance of $820-$860 million, targeting a potential $1 billion+ opportunity in narcolepsy alone.
Harmony ended 2024 with $576 million in cash, cash equivalents and investments. The company highlighted several upcoming catalysts for 2025, including topline data from its Phase 3 trial with ZYN002 in Fragile X syndrome expected in Q3, and the initiation of Phase 3 trials for Pitolisant HD formulation in narcolepsy and idiopathic hypersomnia in Q4.
The company also strengthened its patent position with a favorable settlement of its first generic litigation, giving Novugen Pharma a license to sell its generic product beginning in January 2030 or earlier under certain circumstances. Harmony's pipeline has the potential to deliver over $3 billion in net revenue as it develops innovative treatments across sleep/wake, neurobehavioral, and rare epilepsy franchises.
Harmony Biosciences (NASDAQ: HRMY) received a Refusal to File (RTF) letter from the FDA for pitolisant in treating excessive daytime sleepiness in adult patients with idiopathic hypersomnia (IH). Despite this setback, the company maintains its 2025 net revenue guidance of $820-$860 million.
The company's long-term strategy focuses on Pitolisant HD, an enhanced higher-dose formulation with patent protection until 2044. Harmony plans to initiate a Phase 3 registrational trial of Pitolisant HD in IH in Q4 2025, targeting a PDUFA date in 2028.
While the Phase 3 INTUNE Study's primary outcome didn't reach statistical significance, open-label phase data showed patient improvements five times greater than clinically meaningful levels on the Epworth Sleepiness Scale. The majority of patients maintained normal wakefulness levels beyond one year in the long-term extension study.
Harmony Biosciences (Nasdaq: HRMY) has scheduled its fourth quarter and full year 2024 financial results announcement for February 25, 2025, before U.S. financial markets open. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results.
Participants can join the call by dialing 800-445-7795 (domestic) or 785-424-1699 (international) using passcode HRMYQ424. The company recommends joining the call at least 10 minutes early. Both live and replay versions of the webcast will be available on Harmony's investor relations website.
Harmony Biosciences (HRMY) reported preliminary Q4 2024 net revenue of $201 million and full-year revenue of $714 million for WAKIX, representing 23% growth in its fifth launch year. The company provided 2025 revenue guidance of $820-860 million.
The average number of WAKIX patients increased by 300 to approximately 7,100 in Q4 2024. The company outlined key catalysts for each quarter of 2025, including an FDA decision on pitolisant sNDA for Idiopathic Hypersomnia in Q1, BP1.15205 data presentation at SLEEP 2025 in Q2, ZYN002 Phase 3 topline data for Fragile X Syndrome in Q3, and initiation of Pitolisant-HD Phase 3 trial in Q4.
The company's pipeline is expected to include up to six Phase 3 clinical programs by year-end 2025, with potential to generate over $3 billion in net revenue and deliver at least one new product or indication approval annually through 2028.
Harmony Biosciences Holdings (Nasdaq: HRMY) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Jeffrey M. Dayno, M.D., President and CEO, will present at the conference on January 15, 2025, at 11:15 a.m. PT / 2:15 p.m. ET. Investors and interested parties can access the fireside chat webcast through Harmony's investor relations website.
